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0.001). Controlling for covariates, HR55 patients averaged
$22,502 in paid health care services over 2 years compared to
$15,645 for HR patients and $11,423 for LR patients (p <
0.001). CV costs represented about 46% of costs for the HR55
group, 41% for the HR group, and 31% for the LR group.
CONCLUSION: This study demonstrates the high burden of
illness associated with CVD, especially for patients within the
high risk group aged 55 and over.
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OBJECTIVES: To estimate rates of non-adherence for statins 
following implementation of a preferred drug list (PDL).
METHODS: In a retrospective cohort study, a difference-in-
difference-in-difference approach was used to estimate the
impact of a PDL on statin utilization in an Alabama Medicaid
population. The PDL restricted access to certain branded med-
ications and imposed a monthly prescription limit. The use of
restricted drugs was compared with the use of unrestricted drugs
in the months before and after the PDL in North Carolina (where
there were no such restrictions) and Alabama. Pharmacy data
from 2001 to 2005 were used to examine the effect of the
Alabama PDL implemented in 2004. RESULTS: Following the
PDL in Alabama, Medicaid beneﬁciaries treated with statins had
an 82% higher relative odds of becoming non-adherent with
statin therapy compared with North Carolina and with pre-PDL
Alabama [odds ratio (OR) 1.82, 95% CI 1.57, 2.11]. Further-
more, patients taking a restricted statin were more likely to be
non-adherent than unrestricted patients (OR 1.42, 95% CI 1.12,
1.80). In addition, among Medicaid beneﬁciaries taking a
restricted statin, people aged 65 years or older were more likely
to be non-adherent than their younger counterparts after the
PDL (OR 1.33, 95% CI 1.02, 1.73). Fifty-one per cent of
patients in the Alabama sample were non-adherent with statin
therapy after the PDL, compared with 39% before. Non-adher-
ence was 36% in North Carolina in both periods. CONCLU-
SION: The management of heart disease and high cholesterol are
important challenges, especially for low-income patients. Policy
makers should be aware that access restrictions can have adverse
consequences for patient adherence.
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OBJECTIVES: To develop an evidence-based, real world data
driven interactive model to predict LDL reduction and National
Cholesterol Education Program (NCEP) LDL goal attainment in
patients receiving statin monotherapy. METHODS: An interac-
tive model was developed using data from patients receiving
statins between January 1, 2001 and December 1, 2005 from
two large Southeastern US health plans’ administrative claims
with integrated lab results data. Multivariate OLS regression was
used to predict the percent change in LDL associated with dif-
ferent doses of statin monotherapies for various patient charac-
teristics such as age, gender, NCEP risk factors, presence of
coronary heart disease (CHD) /CHD risk equivalents, and base-
line lipid values. Each patient was assigned a NCEP risk clas-
siﬁcation and corresponding LDL goal, and the patient’s
probability of reaching goal was calculated by simulating a dis-
tribution of the expected percent change and its 95%CI obtained
from the regression. RESULTS: A total of 33,706 patients were
used to build the model. The cohort had a mean age of 54(+10)
years and was 51% male. A total of 41% of patients were clas-
siﬁed as low, 22% as moderate, 30% as high, and 7% as very
high risk based on NCEP criteria. LDL reduction associated with
atorvastatin 10–80 mg, rosuvastatin 5–40 mg and simvastatin
10–80 mg ranged from 35–38%, 31–39% and 24–34%, respec-
tively. The multivariate regression indicated that NCEP risk
status and baseline LDL values were signiﬁcantly associated with
higher reduction in LDL (p < 0.05), independent of type and dose
of statin monotherapy. CONCLUSION: Real world, data driven
interactive models may help decision makers identify patients
that are ideal candidates for cost-effective statin prescribing that
results in substantial cost savings while improving health out-
comes. Models such as this will allow clinicians, health plan
administrators and patients to maximize the economic beneﬁt of
marketplace changes such as generic simvastatin availability in
a clinically appropriate fashion.
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OBJECTIVES: The incorporation of computed tomography
angiography (CTA) scanners into cardiology practices to provide
optimal patient care is increasing. However, little is known about
how these scanners are being used in these practice settings;
therefore, the objective of this study was to assess the real world
CTA procedural mix and volume data from a large cardiovas-
cular practice. METHODS: Data for a one year time period fol-
lowing purchase of a CTA scanner were abstracted from a
moderate size practice consisting of ten cardiologists. A descrip-
tive analysis was conducted to determine the CTA procedural
mix and volume for each of the 12 months that the practice has
owned the CTA scanner. The mix and volume were charted over
time and the average daily procedural volume and mix was quan-
tiﬁed. RESULTS: During the ﬁrst month of ownership, the prac-
tice performed a total of 6 chest studies on the CTA scanner.
However, by the second month of ownership, the total volume
of scans increased to 169 (124 chest, 11 coronary artery calcium
screens, 7 head, 10 neck, 7 abdomen, and 10 legs). The volume
of scans remained consistent for months 3 through 12 with an
average monthly volume of 298 procedures (range 186–384).
Assuming an average of 20 operating days/month, the average
daily procedural volume following the ﬁrst month of ownership
was 14 procedures per day, broken out as follows: chest (7, range
5.6–8.6); coronary artery calcium screen (2, range 0.6–5); head
(0.7, range 0.4–1.3), neck (0.8, range 0.5–1.4); abdomen (0.6,
range 0.4–0.9); pelvis (0.04, range 0–0.2); legs (0.4, range
0–0.7); abdomen with run-off (0.5, range 0–0.9). CONCLU-
SION: Following purchase of a CTA scanner, a cardiology prac-
tice may perform only a few procedures during the ﬁrst month
of ownership; however, the procedural volume and mix sub-
stantially increases during the second month and remains con-
sistent thereafter.
